NCT06228001 Holter of Movement in Patients With Amyotrophic Lateral Sclerosis.
| NCT ID | NCT06228001 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Liege |
| Condition | Amyotrophic Lateral Sclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2023-05-01 |
| Primary Completion | 2028-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2023-05-01 with a primary completion date of 2028-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
ActiALS is a multicentric academic study. Patients with amyotrophic lateral sclerosis (ALS) may be included on a voluntary basis. The investigators plan to include a group of approximately 30 patients with ALS. The investigators have planned to assess patient every three months for a year. After each visit, participants will wear Actimyo for one month daily.
Eligibility Criteria
Inclusion Criteria: * Clinically defined or probable diagnosis of ALS according to El Escorial criteria revised with Awaji's electro-diagnostic algorithm. * Over 18 years old. * Signed informed consent * If patient on Riluzole, the dosage should be stable for 1 month and continued throughout the study period. Exclusion Criteria: * Patients with excessive cognitive disorders, limiting the understanding of task or with apparent communication difficulties hindering data collection. * Any other previous or present pathology having an impact on motor function. * Recent surgery or trauma (less than 6 months) in the upper or lower limbs. * Prior neurological, endocrine, infectious, allergic, or chronic or acute inflammatory pathology in the three weeks preceding inclusion. * Patients participating in an interventional clinical trial.
Contact & Investigator
Stéphanie Delstanche, MD
PRINCIPAL INVESTIGATOR
Centre de référence des maladies neuromusculaire, Centre Hospitalier Régional de la Citadelle
Frequently Asked Questions
Who can join the NCT06228001 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Amyotrophic Lateral Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06228001 currently recruiting?
Yes, NCT06228001 is actively recruiting participants. Contact the research team at laurie.medard@citadelle.be for enrollment information.
Where is the NCT06228001 trial being conducted?
This trial is being conducted at Leuven, Belgium, Liège, Belgium, Cairo, Egypt.
Who is sponsoring the NCT06228001 clinical trial?
NCT06228001 is sponsored by Centre Hospitalier Universitaire de Liege. The principal investigator is Stéphanie Delstanche, MD at Centre de référence des maladies neuromusculaire, Centre Hospitalier Régional de la Citadelle. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.